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Simple Summary: The increasing number of data supporting use of a personalized approach in
cancer treatment, is changing the path of patient’s management. In the same time, the availability
of technologies should allow patients to receive the best test for the specific individual condition.
This is theoretically true, when a specific test is designed for the specific disease condition, while it is
difficult to implement in the setting of agnostic therapies. Financial sources availability related to the
non homogeneous health systems working in the different countries do not allow for an immediate
implementation of the technologies and test commercially available. Future perspectives for targeted
oncology include tumor-agnostic drugs, which target a given mutation and could be used in treating
cancers from multiple organ types. Therefore, the present paper is aimed to both underline a how
much important is this new view and also to sensitize the international bodies that supervise health
policies at the decision-making level, with the aim of harmonizing cancer treatment pathways in at
least all European countries.
Abstract: Rapid and continuing advances in biomarker testing are not being matched by uptake in
health systems, and this is hampering both patient care and innovation. It also risks costing health
systems the opportunity to make their services more efficient and, over time, more economical. The
potential that genomics has brought to biomarker testing in diagnosis, prediction and research is
being realised, pre-eminently in many cancers, but also in an ever-wider range of conditions—notably
BRCA1/2 testing in ovarian, breast, pancreatic and prostate cancers. Nevertheless, the implementation
of genetic testing in clinical routine setting is still challenging. Development is impeded by country-
related heterogeneity, data deficiencies, and lack of policy alignment on standards, approval—and
the role of real-world evidence in the process—and reimbursement. The acute nature of the problem
is compellingly illustrated by the particular challenges facing the development and use of tumour
agnostic therapies, where the gaps in preparedness for taking advantage of this innovative approach
to cancer therapy are sharply exposed. Europe should already have in place a guarantee of universal
access to a minimum suite of biomarker tests and should be planning for an optimum testing scenario
with a wider range of biomarker tests integrated into a more sophisticated health system articulated
around personalised medicine. Improving healthcare and winning advantages for Europe’s industrial
competitiveness and innovation require an appropriate policy framework—starting with an update
to outdated recommendations. We show herein the main issues and proposals that emerged during
the previous advisory boards organised by the European Alliance for Personalized Medicine which
mainly focus on possible scenarios of harmonisation of both oncogenetic testing and management of
cancer patients.
Keywords: Europe’s Healthcare Systems; biomarkers; oncogenomics; HRD; cancers
1. Introduction: Healthcare Efficiencies
Europe is missing out on major opportunities. The rapid growth in the availability
of biomarker testing based on molecular diagnostics has made it possible to improve
European citizens’ health. Widespread adoption would support continued improvements
in outcomes for diseases, already for cancer, and increasingly across a wide range of condi-
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tions. And the prospects are even more attractive if the development and deployment of
more sophisticated biomarkers is encouraged. This would enable exploiting the possibili-
ties of precision medicine—and would drive the evolution of much-needed debate and
definition of the role of real-world evidence. The impact on patients’ health would be more
informed treatment decisions and increased access to targeted treatments, with improved
outcomes. The impact on health systems would be the better deployment of resources that
precision medicine allows [1]. We report herein the proposals that emerged during the
previous advisory boards on this topic. In this regard, some European experts were invited
to join the meetings organized by the European Alliance for Personalized Medicine in order
to share the main criticisms regarding the oncogenetic testing and possible actions to solve
them. None of the participants had any conflicts of interest because the only objective of
the present teamwork is to achieve the harmonization of clinical-diagnostic path of overall
cancer patients.
2. Minimum and Optimum Testing
The short-term need is for an “essential package” of high-quality and timely biomarker
testing across the EU for diagnosis and prevention for all cancer patients. This would
be backed by the certainty of an adequate reimbursement, and up-to-date guidance to
clinicians who had consistent access to clinically meaningful testing results based on
long-term validated biomarkers such as EGFR, HER2, and ALK [2].
Further ahead, an optimum scenario should see multi-modality clinical teams, ade-
quately trained in molecular diagnostics, delivering a high standard of care all over Europe,
and increasingly for patients with other conditions. Pan-cancer research would operate
on the basis of standardized data between multiple platforms, and registries with opt-in
and-out criteria for each disease area would provide more robust data sets—including the
patient’s disease history, outcomes, treatments and genomic aspects, and information on
the use of biomarker tests themselves, such as how often and on which patients [3]. Fuller
use of real-world evidence would provide support for acceptance, and prospects would
mature for wider endorsement of tumour agnostic therapies where genomic data would
allow a focus irrespective of the tumour site of origin [4].
In both paradigms, the aim is to secure the best standard of care for patients. Even
the minimum scenario presupposes readiness to overcome the objective national and local
limitations of resources, human and financial capital and infrastructure. The longer-range
question is how willingly—and how soon—the EU will deploy adequate resources and
political will to embrace an optimum biomarker scenario.
3. Gaps, and Need for Action
At present, progress is impeded by a wide range of barriers.
Although the scientific community has risen well to the innate scientific challenges of
developing sophisticated biomarkers, operational barriers persist in outdated regulations,
inadequate infrastructure for data collection and laboratory analysis, insufficient training
of healthcare professionals, and fragmented approval and funding systems. Technologies,
disease areas, and patient populations vary across Europe, and the apparatus for product
approval of biomarkers is under-developed. Inconsistency persists among evidence frame-
works for diagnostics, and among standards for demonstrating clinical utility, prolonging
uncertainty on reimbursement arrangements.
Health systems are unfamiliar with complex testing systems. Reimbursement of
biomarker tests that are matched to treatments with positive clinical trial data, or for
patients with single mutations, presents fewer challenges because of the link to a single
medicine. Nevertheless, agreement is more elusive when assessing value in molecular
diagnostics monitoring disease or patients’ health, or that prognosticate future disease
progression or that predict whether a patient will have an adverse reaction to a medicine.
And reimbursement remains still more of a challenge, partly because of variations among
key stakeholders in background knowledge and literacy on biomarker testing—and in
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motivation to learn. A general requirement in most countries and regions for new tests to
save costs complicates progress still further [5–7].
The uncertainty on access, funding and uptake of biomarkers based on molecular
diagnostics has a direct negative influence on investment decisions, and impedes innova-
tion and its integration. The disproportion of attention is striking: Diagnostics account
for less than 2% of total healthcare spending—but they influence 60% of clinical decision
making [8]. Current policy in Europe -and particularly in respect of reimbursement—fails
to take this into account, and urgently needs updating [9,10].
4. Upcoming EU Policy Changes
The coronavirus pandemic has given new prominence and impetus to health in EU
policy, but already there was growing consciousness of the combined perils of sub-optimal
health services in the face of demographic change and chronic disease, and of the EU losing
out at world level to the scientific innovation on which its prosperity largely depends [6].
This has given rise to EU plans for a Cancer Mission [7], a Beating Cancer plan,
a European Health Data Space [9,10] that can exploit volumes of data from real world
evidence through exchange among national health data organisations, and the promise of a
new EU pharmaceutical strategy by the end of 2020. These initiatives—now complemented
by the urgent and heavily-funded search for vaccines and treatments to counter Covid-19—
will depend heavily for their success on the extent to which sensitive and sophisticated
testing is available—in other words, for greater use of biomarkers.
5. Need for Updating 2003 Recommendations
Nearly two decades have passed since the emergence in 2003 of EU recommendations
relating to early diagnosis and screening, and in that time the possibilities for better and
more interventive healthcare have increased dramatically. But the operating context for all
stakeholders remains influenced by obsolete thinking. There is an urgent need for updating
EU guidance to take account of progress and the prospects of greater advances.
6. Biomarkers in Action: Clinical Use Cases
It is in oncology that biomarker testing is most evidently proving its worth, in breast,
ovarian, prostate, lung, thyroid and colon cancers [11].
In breast cancer, testing of tumour biopsy now makes it possible to identify certain
mutations that drive treatment resistance, permitting better risk assessment and aiding
the search for targeted therapies [11]. In ovarian cancer, germline mutations in BRCA1
and BRCA2 may support identification of potentially at-risk family members through
cascade testing, or the offer of germline testing to the direct family members of a posi-
tive patient [12,13]. The homologous recombination deficiency (HRD) testing [14] which
incorporates new genomic instability assessment algorithms, offers the opportunity to
enhance the utility for BRCA testing in ovarian, breast, pancreatic and other cancers [14].
Multi-gene expression profiling can prognose outcomes in early-stage breast cancer and
the aggressiveness of prostate cancer, informing treatment decisions, and supporting clini-
cal decision-making inpatients with early stage breast cancer who may require adjuvant
chemotherapy, in whom standard of diagnostic care yields an indeterminate prognosis.
Finally, in prostate cancer, it can support clinical decision making in patients with indeter-
minate risk based on other testing data.
In non-small cell lung cancer, tests for mutations identify patients eligible for tar-
geted therapies [15]: Therefore, biomarker testing offers assistance in defining lung cancer
options, ranging from optimized image-based screening to the use of autoantibodies or
other circulating biomarkers, such as microRNAs and protein panels [11,16]. Molecular
testing for colorectal cancer helps adapting treatment to targeted therapies [17]. In thyroid
cancer, knowing the oncogenic molecular driver helps to determine the aggressiveness
of the tumour and/or to identify the most appropriate systemic or targeted therapy [11].
Across the entire range of cancer—“pan-cancer” as well as tumour agnostics—there is
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potential in the integration of molecular information, identifying actionable mutations with
broad molecular profiling, matching the right targeted therapy to the detected actionable
mutation, and evaluating treatment outcome [5,12]. Applications combining testing using
next generation sequencing with artificial intelligence and machine learning may ultimately
help chart entire clinical pathways [12].
7. Tumour-Agnostic Therapies
These potentially game-changing therapies can supersede the “one size fits all” ap-
proach in oncology, but they require broad next generation sequencing available across
tumour types. Available tumour-agnostic products are already a step towards precision
medicine, but regulators, health technology assessment bodies and consumers are cautious
over the complexities of demonstrating effectiveness in largely unexplored avenues of evi-
dence generation through still-unfamiliar approaches such as basket trials and innovative
methods such as optimized diagnostic algorithms [18]. These therapies are also prompting
new demands for wider understanding of the merits of real-word evidence [4].
8. Potential Solutions
The list of deficiencies and barriers to exploiting the potential of biomarkers is long,
but so too is the list of solutions that are already available—or should be.
Many of the issues relating to funding require only marginal adjustments, via a policy
framework to support diagnostics in the EU by 2022, with a ring-fenced budget allowance
for biomarker testing development and clinical validation, and the promotion of research
investment. But innovative diagnostic technologies lack reimbursement pathways in many
countries, and Health Technology Assessment (HTA) mechanisms connected to a reim-
bursement decision could inspire improvements [19] to develop systems where decision
makers, including HTA bodies informed by input from patients, would define evidentiary
standards for diagnostics and would commit to pay for products that met them [20].
Much can be achieved by more effective collaboration. The EU should agree by 2023 a
business model for public-private cooperation to make optimal biomarker testing available
across the EU, based on the business and value case to provide infrastructure to meet
testing requirements. This would help provide the evidence base on biomarker testing,
and define how it is accessed on a pan-cancer registry across the EU.
Data collection, quality, standards and interoperability need standardisation to allow
clinically-relevant biomarkers to be measured and reported. A federated structure of
national databases would permit large international multi-centre clinical validation studies
of biomarkers (especially early diagnostic and prognostic biomarkers), which require large
and long-lasting cohorts.
An EU framework for quality of testing and value of diagnostics information should
provide standards for laboratories where samples are collected, stabilised and stored. This
would facilitate centralised and standardised registries of diagnosis including sequence
and biomarker data, pre-analytical sample metadata, and treatment and outcome data, and
could feed into a fast-track approval mechanism for biomarker validation, accompanied by
guidance on minimal testing standards and resource allocation [21].
Clarity for clinicians on where and when tests should be performed should be pro-
vided, with captured testing data informing service improvements, benchmarking and
research. A clinical infrastructure that turned fit-for-purpose real world data into real
world evidence would help overcome the deficiencies of existing datasets. And a global
or pan-European pan-cancer registry provide insights valuable learning on sharing data
across borders [22,23].
Collaboration would engage multiple specialties from drug and diagnostic developers,
clinicians, biologists, biostatisticians and digital technology groups, as testing objectives
matured from risk assessment to informing treatment decisions. Member state promotion of
engagement between payer organizations, biomarker developers and the wider healthcare
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stakeholder community would ensure that new validated biomarker tests were rapidly
made available to patients without the imposition of unrealistic evidentiary burdens.
There are opportunities still to be explored—such as providing simpler testing kits for
complex conditions, and notably the development of blood biopsy, or the convergence of
complex test offerings with predictive protein-, genetic- and epigenetic-based biomarkers
or NGS panels, or the development of predictive potential of prognostic tests (effectively
as companion diagnostics) with emerging drugs [11,24,25].
9. The Particular Challenges of Tumour Agnostic Therapies (TAx)
The current gaps and possible solutions apply with added intensity to histology-
independent tumour agnostic therapies (TAx), which differ from conventional anti-cancer
treatments focusing on specific genomic or molecular alterations of cancer cells rather than
the tissue of origin. The same drug has potential to be used to treat various unique types
of cancer, including very rare tumours, as long as the biomarker targeted by the drug is
present [26]. Trials of TAx, especially in rare and ultra-rare populations, face challenges in
generating comparative evidence. Nevertheless, low patient numbers for single tumour
entities with the specific biomarker mean that statistical proof of effect and estimation of
between-tumour heterogeneity are challenging.
The basis of approval for these products is a biomarker present across many tumour
types, and biomarkers that measure response, establishing the effects of context, and
deciphering mechanisms of treatment resistance across a variety of tumour types, also in
the context of basket trials [18–20].
Nonetheless, the European Medicines Agency (EMA) and the US Food and Drug
Administration (FDA) have considered that a high response rate with a long duration of
response in a basket trial can be enough to support a histology independent cancer drug’s
efficacy [18,27,28]. But current approaches to value assessment and the diagnostic infras-
tructure are not adequate, and new approaches have not yet been broadly validated. HTA
bodies are increasingly confronted with large uncertainty in the evidence base available to
inform coverage and reimbursement decisions [28,29].
10. Surveying National Attitudes to Tax
A research regarding the attitudes of clinicians, regulators and academics in several
leading countries revealed the challenges related to the use of TAx [27]. It assessed national
acceptability of basket trials for HTA, for therapies in general, and specifically in the case
of TAx. For TAx, questions related to how far HTA recommendations included efficacy
endpoints beyond overall survival, such as quality of life or clearly measurable biomarkers,
such as the size of tumour; and whether HTA agencies should accept evidence from
uncontrolled, multicentre, open-label, single arm clinical trials [23,29].
The FDA has recently approved two drugs in tissue/site agnostic indications: (a)
Pembrolizumab for the treatment of unresectable or metastatic, microsatellite instability
high or mismatch-repair-deficient solid tumours, irrespective of tumour site or histology
and (b) larotrectinib for solid tumours with a neurotrophic receptor tyrosine kinase gene
fusion. A similar application for larotrectinib to the EMA for evaluation was submitted,
which received a positive opinion by the Committee for Medicinal Products for Human
Use (CHMP). The different pathways for submissions and approval have been deeply
detailed by Wilking et al. [28].
It explored healthcare system reliance on post-authorisation evidence generation to
facilitate patient access to histology independent cancer drugs, the existence of dedicated
HTA pathways for specialised, innovative technologies like TAx, national readiness to
grant conditional patient access until a final recommendation is made on the basis of
further evidence is available (such as after the finalisation of post authorisation studies,
or through the UK Cancer Drugs Fund, and opportunities for conditional reimbursement
arrangements, in general, and specifically for Tax [19,29].
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On testing, the survey inquired into whether routine availability of diagnostic tests—
such as broad panel NGS—is considered a prerequisite for TAx, and whether mechanisms
for reimbursement of diagnostic tests (such as broad panel NGS or WGS) should be separate
from HTA/reimbursement assessments of TAx.
Frequently mentioned barriers to assessing TAx included the lack of comparative
effectiveness, poorly characterized prognostic value of the genomic alteration defining
the tumour-agnostic approach, and limited knowledge on natural history of identified
patients’ populations [25,26,29]. Lack of clarity in the diagnosis pathway, the use of
surrogate endpoints (without evidence on the drug’s efficacy on progression-free survival
and overall survival), inappropriate design, low prevalence or low number of patients
enrolled in studies, often with heterogeneity of previous treatment, were also highlighted.
The innate complexity of the healthcare sector and lack of appropriate regulation were seen
as further obstacles [25].
Our survey detected some willingness to create alignment between regulators and
HTA bodies in terms of evidence sources, endpoint requirements and acceptability of
relevant post-authorisation data collection models, but there was wide recognition of
a lack of consensus over priorities. There appears at present little common ground on
the potentially influential factors to improve the situation—across a range that runs from
government support to adequate infrastructure, via involvement of key stakeholder groups,
increased awareness and understanding of TAx, and adaptive HTA processes. Crucially,
there is currently only little movement to create alignment between regulators and HTA
bodies in terms of evidence sources, endpoint requirements and acceptability of relevant
post authorisation data collection models. Furthermore, readiness in principle to evolve
managed entry agreements beyond discounts is not widely matched by corresponding
action. Similarly, appropriate diagnostic and data infrastructure is not available everywhere,
and is not a priority everywhere.
The experts from the, Canada, France, Germany, Italy, Spain and UK have contributed
to an OHE report of serious gaps in awareness levels among HTA agencies and reluctance
to explore innovative payment mechanisms that go beyond discounts. They commented in
particular on French, German, Canadian and Italian scepticism over evidentiary support
for claims, divergent responses to basket trials in Canada and Italy, and resistance to TAx-
friendly regulation and reimbursement in the UK, Spain and South Korea, The general
absence of widespread and economically acceptable testing constrains progress in TAx, it
was concluded. Although BRCA1/2 and HRD testing represent a paradigm of personalized
treatment in ovarian cancer, the immediate translation to other cancer still challenging due
to some financial and technical issues, the latter particularly related to the failure of test
when applied to low-quality tissues, as it happened in one third of FFPE sample analysed
in the the PROfoud study at ESMO 2019 [30].
The lack of comparative data was however perceived as an understandable—and
at present inevitable—challenge, given the nature of the new entities under study from
a molecular point of view. The immediate issue, therefore, is to identify the level of
uncertainty the different agencies are ready to tolerate, since unflinching insistence on
historical methods for assessing drugs precludes any chance of progress.
Early dialogue is seen as key to mitigating uncertainty, through initial discussion with
relevant bodies at European level to evolve some shared views that could be translated to
the national level and have some influence on discussions on price and reimbursement.
Discussion of uncertainty from a clinical point of view has also led to—for instance—a
framework developed by ESMO to rank genomic alteration, and work of this type could
help advance understanding of the genomic alteration with respect to different cancer types.
Giving specific weight to alterations could help in prioritising treatment options [20,27].
11. Real-World Evidence (RWE)
The discussions of data adequacy are already turning towards the use of real-world
evidence, and highlighting the need for better access so as to confirm where therapies are
Cancers 2021, 13, 583 8 of 12
bringing value to patients. Fragmentation and low prevalence of appropriately digitalised
systems currently inhibit collection of data, with many hospitals and centres still focused
on financial accounting and working on paper. Policy decisions are needed to initiate
improvements, and funding is a further challenge [23–31].
There are signs of some longer-term thinking and even some policy shifts to improve
the situation. The Organisation for Economic Co-operation and Development (OECD)
health ministers have urged health data governance frameworks to ease use of personal
health data for health-related public interest purposes with common data elements and
formats [7]. Challenges in developing RWE include informed consent, and accuracy of
data collected in a “real world” setting. But post-marketing, it can identify adverse effects
in a larger population and in population sub-groups, and contribute to a broader long-term
follow up, on condition of adequate statistical methods to extract, analyse and interpret
real-world data (RWD). Opportunities for patients are lost when science is progressing
faster than the “system”, impeding the development and best use of novel treatment
options. Instead of considering that analysing personal health data is a risk to individuals,
it should be accepted that the reverse is the case: Not analysing personal health data is a
risk to individuals [23,25].
There are a growing number of initiatives to create a federated, interoperable, cross
border data infrastructure that could advance RWE. Examples include Gaia-x [32], led by
figures form politics, business and science in France and Germany, or Medical Informatics
in Germany a multi-stakeholder consortium created to close the gap between research and
healthcare [33]. MedMij in the Netherlands is promoting digital exchange of personal health
data [34], and the French government’s HealthdataHub cross-references health databases
for researchers [35–38]. A recent change in US legislation also combats fragmentation by
limiting the scope for holders of data to actively prevent sharing [39]. A change to the US
CMS final rule requires Medicare and Medicaid participating hospitals to share electronic
notifications with other providers.
12. Tentative Conclusions
Ultimately, successful development and deployment of biomarker testing depends on
a policy framework in which countries would find it easier to reach consistent decisions and
to provide clearer funding arrangements, thus boosting access and continued development.
The EU should take the lead in developing or promoting clear and updated guidance for
regulators and payers/customers, for public and private laboratories, for clinicians and
healthcare providers, on the active development and use of biomarker testing.
There are some signals that could justify guarded hopes of an improved environment.
Recent demonstrations of wide support for EU initiatives such as its Beating Cancer Plan
or its Cancer Mission, as well as numerous declarations made by the EU institutions both
before and during the coronavirus crisis, suggest a growing recognition of the need to
innovate—at the level of both policymakers and of the health community. The renewed
attention to disparities in cancer care and access across Europe is also driving new assess-
ments of obstacles and new pursuits of solutions, and promoting greater networking and
collaboration among cancer institutions.
But nothing will happen by accident. Constructive change to the health care context
could ensure better use of the potential offered by new technologies in testing, in diagnosis
and in treatment of cancer, through development and use of biomarkers and the advanced
treatments—such as personalised medicine and TAx—that they enable. But this will result
only from vigorous debate among all stakeholders, and agreement on recommendations
of a technical and political nature that will result in a better deal for patients and a more
sustainable approach to healthcare.
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13. Recommendations
13.1. Recommendations to the EU
• Update the recommendation on early detection strategies allowing for risk stratifica-
tion through molecular diagnostics/biomarker testing.
• Provide guidance to member states on minimal testing standards (also in light of
IVDR), and on creation of a systematic reference framework for duly-accredited
clinical laboratories.
• Establish a framework promoting the value of diagnostics information and accredited
methodologies for cancer detection and treatment.
• Create a fast track approval mechanism for biomarker validation.
• Consider a 12 month postponement for application of the IVDR.
13.2. Recommendations to EMA
• Early engagement on regulatory qualification of novel biomarkers, and review the
biomarker clinical and analytical validation process.
• Develop multi-stakeholder scientific advice on the use of companion diagnostics.
• Align the post-launch TAx evidence generation commitments with HTAs and
pharma companies.
• Promote consensus on design and set up of confirmatory basket trials.
13.3. Recommendations to Member States
• Ensure that new validated biomarker tests are rapidly made available to patients.
• Incentivize the development and uptake of biomarkers of limited interest to commer-
cial companies (early detection biomarkers & risk biomarkers).
• Synchronise CDx approval processes with drug approval.
• Promote alignment between national regulators and payers/customers on standard-
ized outcome measures, systematic data collection, and data standards and sharing,
and integrate registries for TAx with rare mutations.
• Cooperate on a federated structure of national databases for robust EU-wide data-sets
with uniform criteria and formats for research and real-world data, and standardized
registries of genomics and outcome data.
13.4. Recommendations to All Stakeholders
• Cooperate on information and education, including literacy for the public and for
professionals, with a short-term focus on influencers, notably payers.
• Cooperate on pan-cancer studies, with more, and more targeted, screening, exploiting
the potential of stratification and of genomics, AI, biomarker testing.
13.5. Recommendations on Funding
• The EU to agree by 2023 a business model for public-private cooperation for optimal
biomarker testing available across the EU.
• European health authorities to put in place a policy framework to support diagnos-
tics in the EU by 2022, with a ring-fenced budget allowance for biomarker testing
development (clinical validation).
• Member states to allocate resources specifically for discovery and validation of
biomarkers, and promote engagement between payer organizations, biomarker de-
velopers and the wider healthcare stakeholder community. (vertical integration and
horizontal integration).
• Adaptive reimbursement pathways to be linked to conditional reimbursement based
on evidence development for TAx, with uncertainties mitigated through managed
entry agreements.
• Research to be promoted on biomarkers discovery and early testing.
Cancers 2021, 13, 583 10 of 12
Author Contributions: Conceptualization, D.H., G.C. (Gennaro Ciliberto), G.C. (Giuseppe Curigliano),
P.C., and E.C. (Ettore Capoluongo); methodology: all the Authors; validation: all the Authors; Re-
sources, D.H. and E.C. (Ettore Capoluongo); data curation: All the Authors, Writing—original draft
preparation: D.H., G.C. (Giuseppe Curigliano), C.B. and E.C. (Ettore Capoluongo); writing—review
and editing, D.H. and E.C. (Ettore Capoluongo); supervision: all the Authors; project administration,
D.H. All authors have read and agreed to the published version of the manuscript. The work was
coordinated by D.H., EAPM Executive Director and all authors contributed equally to conceiving,
building and drafting the article with critical input from all co-authors and experts from within the
membership of the European Alliance for Personalised Medicine.
Funding: This work was supported by the in-kind support of the partners of the European Alliance
for Personalised Medicine as well as financial support from Novartis, AstraZeneca, Eli Lilly and
Company, Myriad Genetics.
Institutional Review Board Statement: This work was prepared and approved by a multi-stakeholder
group of authors which included amongst other representatives from patients’ organisations and
scientific societies.
Informed Consent Statement: Not applicable.
Data Availability Statement: Please visit the Website: www.euapm.eu.
Acknowledgments: We would like to thank the members of the European Alliance for Personalised
Medicine, European representatives of the Commission and Member States for their kind input.
Special thanks goes to following experts whose’ advice was invaluable to shape the framework of
the article: Lotte Steuten, Vice President & Head of Consulting, Office of Health Economics; Luis
Paz-Ares, Hospital Doce de Octubre, Madrid, Spain and CIBERONC; David Baldwin, University
of Nottingham; Susana Banerjee, The Royal Marsden NHS Foundation Trust; Reinhard Buttner,
Institute of Pathology, University of Cologne; Fabien Calvo, CancerCore Europe; Dipak Kalra,
The European Institute for Innovation through Health Data (i~HD); Christa Cobbaert, European
Federation of Clinical Chemistry and Laboratory Diagnostics; Jaafar Bennouna, University of Nantes;
Estelle Cauchin, University of Nantes; Iñaki Gutiérrez-Ibarluzea, EuroScan International Network
and BIOEF, Basque Foundation for Health Innovation and Research; Ken Mastris, EuropaUomo;
William Gallagher, University College Dublin; Elżbietę Sarnowską, Maria Skłodowska-Curie Institute
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